Willemijn J. Scholten
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Flow Cytometry-Based Measurable Residual Disease Assessment in Patients With Acute Myeloid Leukemia Receiving Non-Intensive Chemotherapy.
Journal: American journal of hematology
Published: January 29, 2026
Prognostic relevance of limit of quantification as low-level cutoff for flow cytometry-based measurable residual disease assessment in acute myeloid leukemia.
Journal: Leukemia
Published: August 05, 2025
Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial.
Journal: Leukemia
Published: June 09, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents.
Journal: Leukemia
Published: November 09, 2024
The role of the primitive marker CD133 in CD34-negative acute myeloid leukemia for the detection of leukemia stem cells.
Journal: Cytometry. Part B, Clinical cytometry
Published: March 21, 2024
Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML.
Journal: HemaSphere
Published: June 30, 2023
Guided discontinuation of antidepressants: approach and first results of a Dutch multidisciplinary outpatient clinic
Journal: Tijdschrift voor psychiatrie
Published: November 09, 2022
Last Updated: 09/26/2026